trending Market Intelligence /marketintelligence/en/news-insights/trending/ZWLYCtuWhROW0HpvkH08kw2 content esgSubNav
In This List

HLS Therapeutics closes C$50M bought deal offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


HLS Therapeutics closes C$50M bought deal offering

HLS Therapeutics Inc. closed its bought deal offering of 3,126,563 common shares priced at C$16 each, including the exercise in full of the underwriters' overallotment option.

Gross proceeds from the offering are about C$50 million. Net proceeds will be used for business development purposes, including acquisitions of companies and products.

Part of the proceeds will also be used to expand the company's pipeline and fund general corporate purposes and working capital.

The common shares were sold under an underwriting deal between HLS and a syndicate of underwriters co-led by GMP Securities LP and Bloom Burton Securities Inc. and including Clarus Securities Inc. and PI Financial Corp.

Toronto-based HLS Therapeutics sells pharmaceutical products in the specialty central nervous system and cardiovascular markets.